GLP-1 Drugs: More Than Just Weight Loss?

GLP-1 medications are demonstrating significant benefits beyond their initial use for weight loss, with studies revealing positive impacts across multiple organ systems.

These drugs have shown efficacy in reducing inflammation, which is a key factor in cardiovascular disease. They can decrease hospitalizations and deaths in heart failure patients and have been linked to reduced risks of heart attacks and strokes.

Research also indicates GLP-1s can slow the progression of chronic kidney disease and kidney failure. Studies suggest a reduced risk of major cardiovascular events and end-stage kidney disease for diabetic patients.

Furthermore, these medications show promise in treating liver disease, with some studies indicating a reversal of liver scarring. The U.S. Food and Drug Administration has approved Wegovy for treating MASH in adults with excessive liver scarring.

There is also emerging evidence suggesting GLP-1s might reduce the risk of certain cancers. While results for Alzheimer's disease are mixed, some research points to slower cognitive decline and reduced brain volume loss.